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 2 
The past 3 
For many practitioners of in vitro fertilisation (IVF) today, it must be hard to 4 
comprehend the disdain and disgust with which the introduction of IVF as 5 
therapy for infertility was greeted. The ethical and legal wrangling about human 6 
reproductive cloning and the current debate over trans-generational (germline) 7 
genome editing gives a small flavour of how IVF was seen then. What was 8 
regarded as an irrelevant, disruptive and unethical practice is now effectively 9 
mainstream treatment in most countries of the world. 10 
   11 
The journey from bench to bedside was fraught with difficulty – both technical 12 
and social (1). It took almost 10 years from proof of principle of IVF in Robert 13 
Edwards’ Cambridge laboratory to the first live birth 40 years ago in Oldham UK 14 
achieved by Edwards, Steptoe and Purdy. To be an IVF parent then was 15 
considered too shameful to admit, to be an IVF child was to be considered a freak, 16 
and to be an IVF practitioner or to be conducting embryo research led to you 17 
being likened to Frankenstein or Dr. Mengele. Indeed, when Edwards and 18 
Steptoe applied for a Medical Research Council (MRC) grant to fund their work in 19 
1971, they received entirely hostile referees’ reports (2), suggesting that the 20 
referees either did not believe that IVF was able to solve the problem of 21 
infertility or that it was not a problem worth solving. However, despite these 22 
funding setbacks, the hostile social environment in which they worked, and the 23 
many technical problems that they had to overcome, they pressed on undaunted, 24 
buoyed up largely by the many letters from the infertile that they received and 25 
the willing supply of patients that came to their Oldham clinic. The hostile social 26 
and professional environment was such that, even after the births of Louise 27 
Brown in 1978 and Alistair Montgomery in 1979, the situation for Edwards, 28 
Steptoe and Purdy did not improve. As Steptoe had to retire from his NHS post in 29 
Oldham, they sought support from the NHS and the University in Cambridge to 30 
continue the work there, but were unsuccessful, and were, forced to locate and 31 
adapt a private clinic at Bourn Hall, which set them back two years. During this 32 
hiatus, the Australian clinics in Melbourne took the lead, only to be hampered 33 
themselves by the same social abreaction in the form of state legislation that 34 
restricted their capacity to undertake research on human embryos. Edwards, 35 
Steptoe and Purdy started taking patients at Bourn Hall in 1982, the same year 36 
that the Government set up a committee of enquiry into IVF chaired by Mary 37 
Warnock. This committee reported in 1984, and recommended the setting up of 38 
a Human Fertilisation and Embryology Authority (HFEA) to oversee treatment 39 
and research using human embryos. The HFEA finally came into existence in 40 
1990 after a prolonged struggle to salvage embryo research from initially very 41 
hostile houses of parliament (3).  42 
 43 
The Present 44 
Efficacy and safety 45 
Despite the fact that we have much to celebrate by the introduction of IVF, it is 46 
clear that it is a technology whose efficacy, despite continuing improvement, is 47 
still limited (can you imagine any other branch of medicine or surgery accepting 48 
and working with a 70% failure rate?), and its safety is still not fully 49 
demonstrated – live born is not the same as a healthy adult. Potential epigenetic 50 
effects of superovulation, culture conditions, media constituents, and embryo or 51 
gamete manipulation have never been studied long-term (4), and only a few in 52 
the short-term. In the early days of IVF neither the MRC nor the Department of 53 
Health thought IVF important enough to consider long-term follow-up for babies 54 
and still only scant information about health follows the various registers 55 
internationally. At least ICSI was followed up strictly after its introduction in 56 
Belgium, and some preimplantation diagnosis (PGD) centres still follow the 57 
children they have helped to be born free of genetic disease. 58 
 59 
Multiple embryo transfer  60 
Increasing evidence has accumulated from well-designed studies about the 61 
disadvantages and risks of multiple embryo transfer not only in terms of 62 
prematurity with a multiple birth, but also the effects of vanishing twins that 63 
may accompany multiple embryo transfers (5). However, there is still a general 64 
reluctance to move wholly to single embryo transfer; the success of embryo 65 
vitrification is likely to change this, although evidence of its long-term safety is 66 
still being collected.  67 
 68 
Oocyte cryopreservation. 69 
Previously, this was undertaken as a last resort in the face of ageing and lack of a 70 
partner, and was thus too late to be really effective (6). However, freezing of 71 
oocytes as natural insurance against the reduction of fertility with ageing and 72 
against the increased risk of adverse genetic outcomes with age, is a recent 73 
change in practice, and the demand for this is likely to increase further, 74 
especially if the legal time limit of ten years for storage can be relaxed.  75 
 76 
Preimplantation genetic screening and other new technologies 77 
The debate about preimplantation genetic screening for aneuploidy (PGS/PGT-78 
A) has raged for over nearly 25 years, with few good controlled studies, and with 79 
little prospect that well-designed trials with current genetic technologies will be 80 
undertaken, despite opportunities for doing so (7). It seems that priority is given 81 
to making a healthy profit by offering new techniques to vulnerable patients, 82 
rather than first establishing that the techniques are efficacious and safe. Indeed, 83 
the paucity of randomized studies and proper prospective follow-up when new 84 
technologies are introduced is a sad hallmark of the IVF profession today. Is it 85 
not time that our professional societies and Colleges stood firm on the need for 86 
sound scientific rationale, together with an insistence on proper studies and 87 
follow-up, before allowing or supporting the application of new techniques? Is 88 
the absence of such careful studies a consequence of the largely private 89 
treatment of IVF in the UK and the USA? And might the lack of mandatory 90 
guidelines from NICE, leading to the postcode lottery in the provision of IVF on 91 
the NHS, be responsible for this unfortunate situation? 92 
 93 
Role of the HFEA  94 
There are many in the UK who still baulk at the HFE Act, through which 95 
regulation of assisted reproduction occurs, due to a perception that it has been a 96 
brake on research and innovative practice. However, it is noteworthy that the 97 
presence of such regulation has enabled the reasonably smooth public and legal 98 
acceptance of the most recent reproductive technology, mitochondrial 99 
replacement therapy (MRT) for inherited mitochondrial disease (8). The 100 
introduction of MRT here in the UK will be accompanied by mandatory long-101 
term follow-up of offspring (with parental consent). Although not the first 102 
country to undertake MRT, the first case in the USA received significant legal and 103 
ethical criticism for its lack of transparency and lack of proper follow-up and 104 
oversight (9). Moreover, the rapid extension of MRT from avoidance of genetic 105 
disease to infertility therapy in some unregulated countries, despite the lack of 106 
any real scientific basis, gives cause for concern.  107 
 108 
Study of the biology and role of mitochondria in development is blossoming, and 109 
improvement in culture and stem cell technology is allowing us to begin to 110 
understand the processes leading up to gastrulation, which can now be studied 111 
effectively in vitro for the first time (10). All of this has been done within the 112 
window of 14 days of development set out as a legal limit by the HFE Act; this 113 
limit has been followed by some other countries, but not all. Thus, up to now the 114 
Act does not seem to have been a constraint on good laboratory research, 115 
including that of genome editing of embryos (11). The need to know more about 116 
later post-implantation stages, such as gastrulation and germ cell formation, and 117 
the mechanisms governing reproductive success or failure, is likely to reopen 118 
public and legal discussion about the 14 day rule – a pragmatic red line drawn up 119 
as a compromise between public concern and scientific imperative. 120 
 121 
The future 122 
The future for this specialty is likely to be just as interesting and controversial as 123 
the previous 50 years because of its intimate involvement with the reproductive 124 
process and the health of future generations. Indeed, perhaps the biggest 125 
changes that the future brings will not be technological but social and ethical, 126 
with yet further challenges to our established ways of thinking about sex, gender, 127 
sexuality, reproduction, pregnancy and the family. IVF has already contributed to 128 
massive social change and promises to lead to even more! Although the use of 129 
artificial intelligence (AI) and robotics will no doubt make its impact in ART 130 
diagnosis and the IVF laboratory, as it has in diagnostic radiology and repetitive 131 
delicate assembly tasks, it is genome editing in human reproduction that is 132 
probably going to be the most controversial topic in biology for the foreseeable 133 
future. The possibility of editing embryos to remove harmful mutations, or 134 
creating gametes in-vitro from cell lines that have undergone genome editing, 135 
challenges our ethical prejudices and our duties and responsibilities to future 136 
generations (12). Preimplantation Genetic Diagnosis (PGD, or PGT-M as we 137 
currently know it) may no longer be necessary once this new technology 138 
becomes efficacious and safe (13), and the number of embryos that would be 139 
available to be replaced or frozen would be significantly improved over the 140 
current use of PGD which is wholly dependent on finding the unaffected embryos 141 
amongst a small developing cohort. Genome editing in the context might 142 
therefore be regarded as more ethical than PGD, as it would result in the 143 
destruction of fewer embryos. 144 
 145 
In the future, selection for genetic traits compatible with environmental changes 146 
that are happening to our planet may become essential for the survival of our 147 
species, although, for the time being, this remains in the world of science fiction. 148 
 149 
Conclusions 150 
Since its early days as a pariah of clinical and research practice, IVF has come to 151 
occupy a central place in reproductive medicine. With the award of the Nobel 152 
Prize to Bob Edwards in 2010 its important role in science and medicine has also 153 
been recognized. Despite these recognitions, IVF still retains elements of 154 
controversy in its present practice and future prospects, presaging yet more 155 




1. Elder K, Johnson MH. The Oldham Notebooks: an analysis of the 160 
development of IVF 1969-1978. III. Variations in procedures. Reprod Biomed Soc 161 
Online. 2015 Jun;1(1):19-33. 162 
2. Johnson MH, Franklin SB, Cottingham M, Hopwood N. Why the Medical 163 
Research Council refused Robert Edwards and Patrick Steptoe support for 164 
research on human conception in 1971. Hum Reprod. 2010 Sep;25(9):2157-74. 165 
3. Johnson MH, Theodosiou A. PGD and the making of the ‘genetic embryo’ 166 
as a political tool. In: McLean SAM, Elliston S, editors. Regulating Pre-167 
implantation Genetic Diagnosis: Routledge, London; 2012. p. 39-70. 168 
4. Fleming TP, Watkins AJ, Velazquez MA, Mathers JC, Prentice AM, 169 
Stephenson J, et al. Origins of lifetime health around the time of conception: 170 
causes and consequences. Lancet. 2018 May 5;391(10132):1842-52. 171 
5. Kamath MS, Antonisamy B, Selliah HY, Sunkara SK. Perinatal outcomes of 172 
singleton live births with and without vanishing twin following transfer of 173 
multiple embryos: analysis of 113 784 singleton live births. Hum Reprod. 2018 174 
Sep 14. 175 
6. Human Fertilisation and Embryology Authority. Egg Freezing in Fertility 176 
Treatment. Trends and figures 2010-2016.  2018 [17th September 2018]; 177 
Available from: https://www.hfea.gov.uk/media/2656/egg-freezing-in-fertility-178 
treatment-trends-and-figures-2010-2016-final.pdf. 179 
7. Braude P. The emperor still looks naked. Reprod Biomed Online. 2018 180 
Aug;37(2):133-5. 181 
8. Castro RJ. Mitochondrial replacement therapy: the UK and US regulatory 182 
landscapes. J Law Biosci. 2016 Dec;3(3):726-35. 183 
9. Alikani M, Fauser BCJ, Garcia-Valesco JA, Simpson JL, Johnson MH. First 184 
birth following spindle transfer for mitochondrial replacement therapy: hope 185 
and trepidation. Reprod Biomed Online. 2017 Apr;34(4):333-6. 186 
10. Shahbazi MN, Jedrusik A, Vuoristo S, Recher G, Hupalowska A, Bolton V, et 187 
al. Self-organization of the human embryo in the absence of maternal tissues. Nat 188 
Cell Biol. 2016 Jun;18(6):700-8. 189 
11. Ruzo A, Brivanlou AH. At Last: Gene Editing in Human Embryos to 190 
Understand Human Development. Cell Stem Cell. 2017 Nov 2;21(5):564-5. 191 
12. Nuffield Council on Bioethics report: Genome editing and human 192 
reproduction. 2018. 193 
13. Zeng Y, Li J, Li G, Huang S, Yu W, Zhang Y, et al. Correction of the Marfan 194 
Syndrome Pathogenic FBN1 Mutation by Base Editing in Human Cells and 195 
Heterozygous Embryos. Mol Ther. 2018 Aug 14. 196 
 197 
 198 
Acknowledgment: We thank Professor Caroline Ogilvie for her helpful 199 
suggestions and comments in producing this commentary. 200 
 201 
Conflicts and funding: The authors have no conflicts of interest to declare and 202 
have received no funding relevant to preparing this commentary. 203 
 204 
Word count: 1688 205 
 206 
